T1: ACS Treatment Tutoring

Slides:



Advertisements
Similar presentations
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Advertisements

“ If physicians would read two articles per day out of the six million medical articles published annually, in one year, they would fall 82 centuries behind.
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Myocardial Infarction
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
Perspective on COMMIT/CCS-2 Trial of Clopidogrel in STEMI Christopher Cannon, M.D. Brigham and Women’s Hospital Boston, MA.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Clopidogrel 75 mg per day orally should be added to aspirin in patients with STEMI regardless of whether they undergo reperfusion.
Clopidogrel Pretreatment Versus Clopidogrel Exposure Prior to PCI in the ACUITY Trial: Does it Really Matter? Steven R. Steinhubl, Frederick Feit, Antonio.
Applications of bivalirudin in interventional cardiology
Evolution of pharmaceutical antithrombotic therapy in CVD Dr Rob Butler Dept of Cardiology University Hospital of North Staffordshire Drug It!
ACS differentiation: With or without ST- elevation STEMI NSTEMI UAP.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
ACUTE CORONARY SYNDROMES Part I. Definition Acute coronary syndrome (ACS) describes a spectrum of clinical conditions ranging from ST segment elevation.
The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.
Acute Coronary Syndromes. Learning outcomes To understand the clinical spectrum of coronary disease To recognise different presentations of the disease.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Dr.Ali Eshraghi MD Interventional Cardiologist Non STE ACS  Angiographic Findings: 34% 3VD 28%2VD 26%SVD 10%LMCAD Culprit lesion charactristic: eccentric,scalloped,evidence.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Chest Pain in the Emergency Department Junior Teaching C. Brown August 2015.
GENERAL ORDERS PAGE CATH LAB (*50--State "This is an ALPHA page") AS SOON AS POSSIBLE Complete STEMI Checklist Start 1-2 venous access lines Nasal oxygen.
Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
Acute Coronary Syndrome
Therapeutics Tutoring
CPR in ACUTE CORONARY SYNDROM
Cardiac causes of cardiac arrest
Liver Disease tutoring Part 1
Pharmacotherapy Update for STEMI: What Is New?
Heparin Should be the First-line Therapy for Patients with ACS/AMI
The American College of Cardiology Presented by Dr. Adnan Kastrati
Guidelines for the Management of Patients With ST- Elevation Myocardial Infarction Adapted from Focused Updates: ACC/AHA 2009.
T1: Post ACS Treatment Tutoring
Management of ST-Elevation Myocardial Infarction
Antiplatelet therapy for STEMI
Dyslipidemia and Primary Prevention
Ischaemic Heart Disease Acute Coronary Syndrome
Dr. Harvey White on behalf of the ACUITY investigators
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Unstable Angina and Non–ST Elevation Myocardial Infarction
European Heart Association Journal 2007 April
Eugene Braunwald, MD, Marc S. Sabatine, MD, MPH 
Section F: Clinical guidelines
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
Implications of Preoperative Thienopyridine Use
on behalf of the ACUITY investigators
© 2004 American Heart Association
Acute Coronary Syndrome (1)
What oral antiplatelet therapy would you choose?
Intermediate/low-risk UA
Nat. Rev. Cardiol. doi: /nrcardio
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Infarct Size after Primary Angioplasty Patients With Bivalirudin
Is Bivalirudin Monotherapy Sufficient for Diabetic Patients
Baseline Characteristics
Train-the-Trainer Cases
Management of AMI in patients presenting with STEMI
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
Train-the-Trainer Cases
Train-the-Trainer Cases
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
Presentation transcript:

T1: ACS Treatment Tutoring By Alaina Darby

Which of the following can be used to differentiate NSTEMI from UA? ST elevation Troponin levels Rapidity of onset EKG B… this is the only thing!

Which of the following best describes the pathophysiology of STEMI? Plaque disruption that partially occludes the vessel and releases troponin Plaque disruption that partially occludes the vessel and does not release troponin Plaque disruption that totally occludes the vessel and releases troponin Plaque disruption that totally occludes the vessel and does not release troponin C

Case: AK is a 43 yo WF who presents to the ED with chest pain. She reports that she has been experiencing chest pain for 1 hour prior to arrival to the ED PMH: diabetes, HTN, TIA PSH: bilateral oophorectomy SH: smokes ½ ppd, denies alcohol use, denies elicit drug use FH: father died of MI at age 60 Vitals/Labs: BMI: 34 HDL: 21 LDL: 100 Troponin: negative EKG: T wave inversion, ST segment elevation, and Q wave normal

How many modifiable risk factors does AK have? 3 4 5 6 AK is a 43 yo WF who presents to the ED with chest pain. She reports that she has been experiencing chest pain for 1 hour prior to arrival to the ED. PMH: diabetes, HTN, TIA PSH: bilateral oophorectomy SH: smokes ½ ppd, denies alcohol use, denies elicit drug use FH: father died of MI at age 60 Vitals/Labs: BMI: 34, HDL: 21, LDL: 100, Troponin: negative, EKG: T wave inversion, ST segment elevation, and Q wave normal How many modifiable risk factors does AK have? 3 4 5 6 C… DM, HTN, smoking, obesity, HDL

How many non-modifiable risk factors does AK have? 1 2 3 AK is a 43 yo WF who presents to the ED with chest pain. She reports that she has been experiencing chest pain for 1 hour prior to arrival to the ED. PMH: diabetes, HTN, TIA PSH: bilateral oophorectomy SH: smokes ½ ppd, denies alcohol use, denies elicit drug use FH: father died of MI at age 60 Vitals/Labs: BMI: 34, HDL: 21, LDL: 100, Troponin: negative, EKG: T wave inversion, ST segment elevation, and Q wave normal How many non-modifiable risk factors does AK have? 1 2 3 A

AK should be diagnosed with what? NSTEMI UA STEMI Cannot be determined AK is a 43 yo WF who presents to the ED with chest pain. She reports that she has been experiencing chest pain for 1 hour prior to arrival to the ED. PMH: diabetes, HTN, TIA PSH: bilateral oophorectomy SH: smokes ½ ppd, denies alcohol use, denies elicit drug use FH: father died of MI at age 60 Vitals/Labs: BMI: 34, HDL: 21, LDL: 100, Troponin: negative, EKG: T wave inversion, ST segment elevation, and Q wave normal AK should be diagnosed with what? NSTEMI UA STEMI Cannot be determined C

Which of the following occurs first on the EKG? ST segment elevation T wave inversion Pathological Q waves B

Which is not indicative of myocardial injury? ST segment elevation T wave inversion Pathological Q waves B

AK is a 43 yo WF who presents to the ED with chest pain AK is a 43 yo WF who presents to the ED with chest pain. She reports that she has been experiencing chest pain for 1 hour prior to arrival to the ED. PMH: diabetes, HTN, TIA PSH: bilateral oophorectomy SH: smokes ½ ppd, denies alcohol use, denies elicit drug use FH: father died of MI at age 60 Vitals/Labs: BMI: 34, HDL: 21, LDL: 100, Troponin: negative, EKG: T wave inversion, ST segment elevation, and Q wave normal Should her ST segment not be elevated, AK should be diagnosed with what? NSTEMI UA STEMI Cannot be determined D

Which medications should be administered within the first 24-48 hours? AK is a 43 yo WF who presents to the ED with chest pain. She reports that she has been experiencing chest pain for 1 hour prior to arrival to the ED. PMH: diabetes, HTN, TIA PSH: bilateral oophorectomy SH: smokes ½ ppd, denies alcohol use, denies elicit drug use FH: father died of MI at age 60 Vitals/Labs: BMI: 34, HDL: 21, LDL: 100, Troponin: negative, EKG: T wave inversion, ST segment elevation, and Q wave normal Which medications should be administered within the first 24-48 hours? ASA 81 mg, Clopidogrel 600 mg, UFH 60 units/kg ASA 162 mg, Clopidogrel 300 mg, UFH 60 units/kg ASA 325 mg, Clopidogrel 300 mg, UFH 12 units/kg ASA 325 mg, Clopidogrel 75 mg, UFH 60 units/kg B

Which medication regimen would be appropriate if AK will undergo PCI? AK is a 43 yo WF who presents to the ED with chest pain. She reports that she has been experiencing chest pain for 1 hour prior to arrival to the ED. PMH: diabetes, HTN, TIA PSH: bilateral oophorectomy SH: smokes ½ ppd, denies alcohol use, denies elicit drug use FH: father died of MI at age 60 Vitals/Labs: BMI: 34, HDL: 21, LDL: 100, Troponin: negative, EKG: T wave inversion, ST segment elevation, and Q wave normal Which medication regimen would be appropriate if AK will undergo PCI? ASA 81 mg, Clopidogrel 600 mg, UFH 12 units/kg ASA 162 mg, Ticagrelor 180 mg, UFH 60 units/kg ASA 325 mg, Clopidogrel 75 mg, Bivalirudin ASA 325 mg, Ticagrelor 90 mg, Bivalirudin B

ASA/ticagrelor/eptifibatide ASA/clopidogrel/heparin AK is a 43 yo WF who presents to the ED with chest pain. She reports that she has been experiencing chest pain for 1 hour prior to arrival to the ED. PMH: diabetes, HTN, TIA PSH: bilateral oophorectomy SH: smokes ½ ppd, denies alcohol use, denies elicit drug use FH: father died of MI at age 60 Vitals/Labs: BMI: 34, HDL: 21, LDL: 100, Troponin: negative, EKG: T wave inversion, ST segment elevation, and Q wave normal Which medication regimen would be appropriate if AK is undergoing a thrombolytic approach (in addition to tPA)? ASA/ticagrelor/eptifibatide ASA/clopidogrel/heparin ASA/heparin/eptifibatide ASA/ticagrelor/bivaliruden B

Clopidogrel/ Ticagrelor ACS Non-invasive ASA Clopidogrel/ Ticagrelor UFH/ Enoxaparin Reperfusion Thrombolytic Clopidogrel Invasive (PCI) Clopidogrel/ Ticagrelor/ Prasugrel One of the following: UFH/ Enoxaparin and GP IIb/IIIa Bivalirudin

ASA/enoxaparin/ticagrelor ASA/heparin/prasugrel ASA/heparin/ticagrelor AK is a 43 yo WF who presents to the ED with chest pain. She reports that she has been experiencing chest pain for 1 hour prior to arrival to the ED. PMH: diabetes, HTN, TIA PSH: bilateral oophorectomy SH: smokes ½ ppd, denies alcohol use, denies elicit drug use FH: father died of MI at age 60 Vitals/Labs: BMI: 34, HDL: 21, LDL: 100, Troponin: negative, EKG: T wave inversion, ST segment elevation, and Q wave normal Should AK be diagnosed with NSTEMI and undergo PCI, which of the following would not be indicated for her? ASA/enoxaparin/ticagrelor ASA/heparin/prasugrel ASA/heparin/ticagrelor ASA/heparin/clopidogrel B

Which of the following must always be used with bivalirudin? ASA GP IIb/IIIa inhibitor Enoxaparin Heparin A… also thienopyridine

Which of the following can be used as an alternate to ASA if the patient has an allergy? Clopidogrel Prasugrel Ticagrelor A

Which of the following cannot be used in combination with ASA for a patient with UA/NSTEMI? Clopidogrel Prasugrel Ticagrelor B

If a patient undergoes the noninvasive approach, which of the following is an acceptable regimen? ASA continued 1 year afterward + clopidogrel continued 1 year afterward ASA continued 1 year afterward + prasugrel continued 1 year afterward ASA continued indefinitely + clopidogrel continued 1 month afterward ASA continued indefinitely + prasugrel continued 1 year afterward C

If a GK is 65 yo and undergoes thrombolytic therapy due to STEMI, which of the following should be his regimen? Clopidogrel 300 mg loading dose followed by 75 mg/day for 1 year Clopidogrel 300 mg loading dose followed by 75 mg/day for 1 month Clopidogrel 200 mg loading dose followed by 75 mg/day for 1 year Clopidogrel 200 mg loading dose followed by 75 mg/day for 1 month A

Which of the following should be withheld 7 days prior to CABG? Clopidogrel Prasugrel Ticagrelor B

For invasive therapy for UA/NSTEMI, which of the following regimens should be used in a high risk patient? ASA, heparin, GPIIb/IIIa, and prasugrel ASA, heparin, and prasugrel ASA, heparin, GPIIb/IIIa, and clopidogrel ASA, heparin, and clopidogrel A or C B or D C or D C

For invasive therapy for UA/NSTEMI, which of the following regimens should be used in a low risk patient? ASA, heparin, GPIIb/IIIa, and prasugrel ASA, heparin, and prasugrel ASA, heparin, GPIIb/IIIa, and clopidogrel ASA, heparin, and clopidogrel A or C B or D C or D F